Akebia Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	236.2	160.18	194.62	292.48	211.65
Revenue Growth (YoY)	47.46%	-17.70%	-33.46%	38.19%	-28.17%
Cost of Revenue	39.46	63.18	74.15	85.57	150.67
Gross Profit	196.73	97	120.47	206.92	60.98
Selling, General & Admin	107.48	106.55	100.23	138.6	174.14
Research & Development	62.36	37.65	63.08	129.99	147.85
Other Operating Expenses	3.4	3.28	3.42	19.11	3.49
Total Operating Expenses	173.24	147.48	166.73	287.7	325.48
Operating Income	23.5	-50.47	-46.26	-80.78	-264.5
Interest Expense	-24.18	-18.19	-6.03	-15.69	-
Other Non-Operating Income (Expense)	-3.04	-0.75	0.36	2.24	-17.52
Total Non-Operating Income (Expense)	-27.22	-18.94	-5.67	-13.45	-17.52
Pretax Income	-3.72	-69.41	-51.93	-94.23	-282.02
Provision for Income Taxes	1.62	-	-	-	-
Net Income	-5.35	-69.41	-51.93	-94.23	-282.02
Net Income to Common	-5.35	-69.41	-51.93	-94.23	-282.02
Shares Outstanding (Basic)	257	211	187	183	166
Shares Outstanding (Diluted)	257	211	187	183	166
Shares Change (YoY)	21.91%	12.53%	2.56%	10.14%	19.85%
EPS (Basic)	-0.02	-0.33	-0.28	-0.52	-1.70
EPS (Diluted)	-0.02	-0.33	-0.28	-0.52	-1.70
Free Cash Flow	67.7	-40.69	-23.38	-73.27	-253.02
Free Cash Flow Per Share	0.26	-0.19	-0.12	-0.40	-1.52
Gross Margin	83.29%	60.56%	61.90%	70.74%	28.81%
Operating Margin	9.95%	-31.51%	-23.77%	-27.62%	-124.97%
Profit Margin	-2.26%	-43.33%	-26.68%	-32.22%	-133.25%
FCF Margin	28.66%	-25.40%	-12.02%	-25.05%	-119.55%
EBITDA	24.77	-12.97	-8.63	-43.08	-226.53
EBITDA Margin	10.49%	-8.10%	-4.43%	-14.73%	-107.03%
EBIT	23.5	-50.47	-46.26	-80.78	-264.5
EBIT Margin	9.95%	-31.51%	-23.77%	-27.62%	-124.97%
Effective Tax Rate	-43.64%	0.00%	0.00%	0.00%	0.00%

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q